BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-line treatment of chronic myeloid leukemia in chronic phase (CML-CP). Less is known about mutation development during first-line treatment with dasatinib and nilotinib, despite increased use because of h...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, T P, Saglio, G, Quintás-Cardama, A, Mauro, M J, Kim, D-W, Lipton, J H, Bradley-Garelik, M B, Ukropec, J, Hochhaus, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559757/
https://www.ncbi.nlm.nih.gov/pubmed/26118315
http://dx.doi.org/10.1038/leu.2015.168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559757/
https://www.ncbi.nlm.nih.gov/pubmed/26118315
http://dx.doi.org/10.1038/leu.2015.168

Ejemplares similares